MarketLens

Pricing Plans Sign Up Log in

Stock Analysis Pro

What Did D3 Bio Present at ASCO 2026 for Elisrasib

9 hours ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What Makes Akeso's ASCO 2026 Plenary Session So Crucial

5 days ago

What is Latus Bio's "Gene Therapy 2.0" and Why Does it Matter

3 weeks ago

Is PetroChem Innovate's New Bio-Plastic a Game Changer for the Industry

1 months ago

What's Driving TELA Bio's Board Refreshment and Strategic Shift

1 months ago

D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC

D3 Bio reported first-line clinical data for its next-generation KRAS G12C inhibitor, elisrasib (D3S-001), at the ASCO 2026 conference. The study highlights landmark efficacy results for the drug in p...

Stock News•1 day ago

Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting

Immunome presented Phase 3 RINGSIDE trial data for varegacestat in adults with progressing desmoid tumors at the 2026 ASCO Annual Meeting. The results detail the efficacy and safety profile of the tar...

IMNM

Stock News•1 week ago

Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

Pliant Therapeutics will present data from its Phase 1b FORTIFY trial at the 2026 ASCO Annual Meeting in Chicago, running May 29 to June 2. The presentation highlights PLN-101095 in patients with ICI-...

PLRX

Stock News•1 week ago

Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting

Olema Oncology reported encouraging initial Phase 1 data for its KAT6 inhibitor, OP-3136, at the 2026 ASCO Annual Meeting. The drug demonstrated anti-tumor activity across multiple solid tumor types a...

OLMA